pimagedine has been researched along with Diabetic Nephropathies in 61 studies
pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure
aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Both aminoguanidine and perindopril retarded the increase in albuminuria, which was completely abrogated by combination therapy." | 3.72 | Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. ( Allen, TJ; Burns, WC; Cooper, ME; Davis, BJ; Forbes, JM; Jerums, G; Kawachi, H; Thomas, MC, 2004) |
| " During the interdialytic period, the maximum aminoguanidine concentration (Cmax) and time to reach Cmax was 4." | 2.68 | The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis. ( Foote, EF; Giles, P; Halstenson, CE; Keane, WF; Look, ZM, 1995) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease, and both the incidence and prevalence of diabetic nephropathy continue to increase." | 2.46 | Potential new therapeutic agents for diabetic kidney disease. ( Bolton, WK; Turgut, F, 2010) |
| "The role of AGEs in diabetic nephropathy has been established by years of basic research." | 2.42 | Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. ( Williams, ME, 2004) |
| "Diabetic nephropathy is becoming a major medical problem with increasing numbers of these patients progressing to end stage renal disease, thus requiring renal replacement therapy." | 2.41 | Pimagedine: a novel therapy for diabetic nephropathy. ( Abdel-Rahman, E; Bolton, WK, 2002) |
| "Renal functional decline in diabetic nephropathy is slowed by establishment of euglycaemia and normalization of hypertensive blood pressure." | 2.40 | Advanced glycation end-products in diabetic nephropathy. ( Friedman, EA, 1999) |
| "A mouse model for diabetic nephropathy that encompasses the salient features of this disease in the kidney is not available." | 1.34 | Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. ( Grahovac, G; Kalluri, R; Sugimoto, H; Zeisberg, M, 2007) |
| "Humans with type 2 diabetes and nephropathy displayed similar alterations in MMP-7 to their rodent counterparts." | 1.34 | Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy? ( Dy, V; Gilbert, RE; Kelly, DJ; Langham, RG; McLennan, SV; Schache, M; Waltham, M; Yue, DK, 2007) |
| "The severe diabetic nephropathy that develops in the hypertensive transgenic (mRen-2)27 rat with streptozotocin (STZ) diabetes has previously been considered angiotensin II-dependent." | 1.31 | ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. ( Cooper, ME; Davis, B; Jaworski, K; Kelly, DJ; Koerner, SM; Thallas, V; Wilkinson-Berka, JL, 2002) |
| "Cataract was observed in all six of the surviving rats in Groups 2 and 4, and in one of 6 surviving rats in group 3." | 1.31 | Effects of aminoguanidine and tolrestat on the development of ocular and renal structural changes in experimental diabetic rats. ( Azal, O; Baydar, A; Cakir, B; Corakçi, A; Güler, S; Kutlu, M; Yönem, A, 2002) |
| "These results indicate that diabetic nephropathy is not linked to homocysteinemia in the rat." | 1.31 | A study on the relationship between homocysteine and diabetic nephropathy in rats. ( Bekpinar, S; Gürdöl, F; Seferoğlu, G; Unlüçerçi, Y, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.64) | 18.7374 |
| 1990's | 20 (32.79) | 18.2507 |
| 2000's | 33 (54.10) | 29.6817 |
| 2010's | 7 (11.48) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Song, Y | 1 |
| Zhang, F | 1 |
| Ying, C | 1 |
| Kumar, KA | 1 |
| Zhou, X | 1 |
| Zheng, N | 1 |
| Lin, X | 1 |
| Wen, Q | 1 |
| Zhang, S | 1 |
| Huang, J | 1 |
| Xu, X | 1 |
| Huang, R | 1 |
| Wang, S | 1 |
| Li, B | 1 |
| Li, C | 1 |
| Cui, W | 1 |
| Miao, L | 1 |
| El Shazly, AH | 1 |
| Mahmoud, AM | 1 |
| Darwish, NS | 1 |
| Turgut, F | 1 |
| Bolton, WK | 2 |
| Li, Q | 1 |
| Ao, X | 1 |
| Du, Y | 1 |
| Li, Y | 1 |
| Ou, Y | 1 |
| Gong, R | 1 |
| Sun, X | 1 |
| Yang, YX | 1 |
| Wen, G | 1 |
| Hu, C | 1 |
| Cong, XD | 1 |
| Dai, DZ | 1 |
| Zhang, Y | 1 |
| Zhang, GL | 1 |
| Dai, Y | 1 |
| Nordquist, L | 1 |
| Liss, P | 1 |
| Fasching, A | 1 |
| Hansell, P | 1 |
| Palm, F | 1 |
| Miyoshi, H | 1 |
| Taguchi, T | 1 |
| Sugiura, M | 1 |
| Takeuchi, M | 1 |
| Yanagisawa, K | 1 |
| Watanabe, Y | 1 |
| Miwa, I | 1 |
| Makita, Z | 2 |
| Koike, T | 1 |
| Kawakami, M | 1 |
| Kuroki, M | 1 |
| Forbes, JM | 6 |
| Cooper, ME | 12 |
| Thallas, V | 3 |
| Burns, WC | 3 |
| Thomas, MC | 2 |
| Brammar, GC | 1 |
| Lee, F | 1 |
| Grant, SL | 1 |
| Burrell, LM | 1 |
| Burrell, LA | 1 |
| Jerums, G | 11 |
| Osicka, TM | 2 |
| Wilkinson-Berka, JL | 1 |
| Kelly, DJ | 4 |
| Koerner, SM | 1 |
| Jaworski, K | 1 |
| Davis, B | 1 |
| Twigg, SM | 1 |
| Cao, Z | 1 |
| MCLennan, SV | 3 |
| Brammar, G | 1 |
| Thornalley, PJ | 1 |
| Panagiotopoulos, S | 4 |
| Forbes, J | 1 |
| Osicka, T | 1 |
| Cooper, M | 2 |
| Davis, BJ | 1 |
| Kawachi, H | 1 |
| Allen, TJ | 1 |
| Ishikawa, N | 1 |
| Miyata, T | 2 |
| Kurokawa, K | 1 |
| Biswas, SK | 1 |
| de Faria, JM | 1 |
| de Faria, JB | 1 |
| Thallas-Bonke, V | 1 |
| Lindschau, C | 1 |
| Rizkalla, B | 1 |
| Bach, LA | 2 |
| Boner, G | 1 |
| Meier, M | 1 |
| Haller, H | 1 |
| Williams, ME | 1 |
| Rosca, MG | 1 |
| Mustata, TG | 1 |
| Kinter, MT | 1 |
| Ozdemir, AM | 1 |
| Kern, TS | 1 |
| Szweda, LI | 1 |
| Brownlee, M | 2 |
| Monnier, VM | 1 |
| Weiss, MF | 1 |
| Yamamoto, M | 1 |
| Izuhara, Y | 1 |
| Coughlan, MT | 1 |
| Pala, L | 1 |
| Cresci, B | 1 |
| Manuelli, C | 1 |
| Maggi, E | 1 |
| Yamaguchi, YF | 1 |
| Cappugi, P | 1 |
| Rotella, CM | 1 |
| Giannini, S | 1 |
| Sugimoto, H | 1 |
| Grahovac, G | 1 |
| Zeisberg, M | 1 |
| Kalluri, R | 1 |
| Schache, M | 1 |
| Waltham, M | 1 |
| Dy, V | 1 |
| Langham, RG | 1 |
| Yue, DK | 3 |
| Gilbert, RE | 3 |
| He, H | 1 |
| Yang, X | 1 |
| Zeng, X | 1 |
| Shi, M | 1 |
| Yang, J | 1 |
| Wu, L | 1 |
| Li, L | 1 |
| Kang, KS | 1 |
| Yamabe, N | 1 |
| Kim, HY | 1 |
| Yokozawa, T | 1 |
| Friedman, EA | 4 |
| Bucala, R | 3 |
| Vlassara, H | 4 |
| Yang, CW | 1 |
| Striker, GE | 1 |
| Striker, LJ | 1 |
| Castellino, P | 1 |
| Tuttle, KR | 1 |
| DeFronzo, RA | 1 |
| Soulis-Liparota, T | 2 |
| Dunlop, M | 1 |
| Foote, EF | 1 |
| Look, ZM | 1 |
| Giles, P | 1 |
| Keane, WF | 1 |
| Halstenson, CE | 1 |
| Vega, G | 1 |
| Grundy, S | 1 |
| Koschinsky, T | 1 |
| Cerami, A | 1 |
| Fisher, EJ | 1 |
| Turtle, JR | 1 |
| Miyauchi, Y | 1 |
| Shikama, H | 1 |
| Takasu, T | 1 |
| Okamiya, H | 1 |
| Umeda, M | 1 |
| Hirasaki, E | 1 |
| Ohhata, I | 1 |
| Nakayama, H | 1 |
| Nakagawa, S | 1 |
| Oturai, PS | 1 |
| Rasch, R | 1 |
| Hasselager, E | 1 |
| Johansen, PB | 1 |
| Yokoyama, H | 1 |
| Thomsen, MK | 1 |
| Myrup, B | 1 |
| Kofoed-Enevoldsen, A | 1 |
| Deckert, T | 1 |
| Soulis, T | 4 |
| Vranes, D | 1 |
| Distant, DA | 1 |
| Fleishhacker, JF | 1 |
| Boyd, TA | 1 |
| Cartwright, K | 2 |
| Youssef, S | 2 |
| Nguyen, DT | 1 |
| Freedman, BI | 1 |
| Wuerth, JP | 1 |
| Bain, RP | 1 |
| Dippe, S | 1 |
| Hershon, K | 1 |
| Mooradian, AD | 1 |
| Spinowitz, BS | 1 |
| Birrell, AM | 1 |
| Heffernan, SJ | 1 |
| Ansselin, AD | 1 |
| McLennan, S | 1 |
| Church, DK | 1 |
| Gillin, AG | 1 |
| Dean, R | 1 |
| Menè, P | 1 |
| Festuccia, F | 1 |
| Polci, R | 1 |
| Pugliese, F | 1 |
| Cinotti, GA | 1 |
| Long, DM | 1 |
| Vasan, S | 1 |
| Wagle, D | 1 |
| Kiriazis, Z | 1 |
| Pratt, LM | 1 |
| Comper, WD | 1 |
| Cox, AJ | 2 |
| Brown, CD | 1 |
| Zhao, ZH | 1 |
| Thomas, LL | 1 |
| deGroof, R | 1 |
| Degenhardt, TP | 1 |
| Alderson, NL | 1 |
| Arrington, DD | 1 |
| Beattie, RJ | 1 |
| Basgen, JM | 1 |
| Steffes, MW | 1 |
| Thorpe, SR | 1 |
| Baynes, JW | 1 |
| Azal, O | 1 |
| Yönem, A | 1 |
| Güler, S | 1 |
| Cakir, B | 1 |
| Baydar, A | 1 |
| Corakçi, A | 1 |
| Kutlu, M | 1 |
| Unlüçerçi, Y | 1 |
| Bekpinar, S | 1 |
| Gürdöl, F | 1 |
| Seferoğlu, G | 1 |
| Abdel-Rahman, E | 1 |
| Aaltonen, P | 1 |
| Rumble, JR | 1 |
| Langham, R | 1 |
| Holthöfer, H | 1 |
| Edelstein, D | 1 |
| Papazoglou, D | 1 |
| Clarke, B | 1 |
| Kumari, K | 1 |
| Murthy, PS | 1 |
| Sahib, MK | 1 |
| Nicholls, K | 1 |
| Mandel, TE | 1 |
13 reviews available for pimagedine and Diabetic Nephropathies
| Article | Year |
|---|---|
Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy.
Topics: Animals; Anthocyanins; Antibodies, Monoclonal; Connective Tissue Growth Factor; Diabetes Mellitus; D | 2015 |
Potential new therapeutic agents for diabetic kidney disease.
Topics: Amides; Animals; Clinical Trials as Topic; Connective Tissue Growth Factor; Diabetic Nephropathies; | 2010 |
[Aminoguanidine and other AGE inhibitors].
Topics: Amides; Animals; Arteriosclerosis; Cardiovascular Diseases; Cataract; Clinical Trials as Topic; Diab | 2002 |
Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts.
Topics: Animals; Diabetic Nephropathies; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glycation End | 2003 |
Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Type 2; Diabetic | 2003 |
[Carbonyl stress inhibitor towards new therapeutic interventions in diabetic nephropathy].
Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihyp | 2004 |
Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease.
Topics: Diabetic Nephropathies; Enzyme Inhibitors; Glycation End Products, Advanced; Guanidines; Humans; Mod | 2004 |
Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?
Topics: Animals; Diabetic Nephropathies; Disease Models, Animal; Glycation End Products, Advanced; Guanidine | 2005 |
Advanced glycosylation endproducts in diabetic renal disease: clinical measurement, pathophysiological significance, and prospects for pharmacological inhibition.
Topics: Animals; Carbohydrates; Diabetic Nephropathies; Endothelium, Vascular; Glycosylation; Guanidines; Hu | 1995 |
Serum advanced glycosylation end products: a new class of uremic toxins?
Topics: Animals; Blood Proteins; Combined Modality Therapy; Diabetes Mellitus, Experimental; Diabetic Nephro | 1994 |
Advanced glycation end-products in diabetic nephropathy.
Topics: Animals; Diabetic Nephropathies; Enzyme Inhibitors; Female; Glucose; Glycation End Products, Advance | 1999 |
Diabetic nephropathy and advanced glycation end products.
Topics: Calcium Signaling; Diabetic Nephropathies; Glomerular Mesangium; Glycation End Products, Advanced; G | 2001 |
Pimagedine: a novel therapy for diabetic nephropathy.
Topics: Animals; Diabetic Nephropathies; Drug Evaluation, Preclinical; Glycation End Products, Advanced; Gua | 2002 |
4 trials available for pimagedine and Diabetic Nephropathies
| Article | Year |
|---|---|
The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis.
Topics: Diabetic Nephropathies; Female; Guanidines; Half-Life; Humans; Kidney; Kidney Failure, Chronic; Male | 1995 |
Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency.
Topics: Animals; Cholesterol; Diabetes Mellitus; Diabetic Nephropathies; Enzyme-Linked Immunosorbent Assay; | 1994 |
Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Administra | 1999 |
Effects of erythropoietin and aminoguanidine on red blood cell deformability in diabetic azotemic and uremic patients.
Topics: Area Under Curve; Diabetic Nephropathies; Drug Therapy, Combination; Erythrocyte Deformability; Eryt | 2001 |
44 other studies available for pimagedine and Diabetic Nephropathies
| Article | Year |
|---|---|
Inhibition of NF-κB activity by aminoguanidine alleviates neuroinflammation induced by hyperglycemia.
Topics: Animals; Brain; Calcium-Binding Proteins; Cytoplasm; Diabetes Mellitus, Experimental; Diabetic Nephr | 2017 |
Effect of 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione, isolated from Averrhoa carambola L. (Oxalidaceae) roots, on advanced glycation end-product-mediated renal injury in type 2 diabetic KKAy mice.
Topics: Administration, Oral; Animals; Antioxidants; Blotting, Western; Cyclohexenes; Diabetes Mellitus, Exp | 2013 |
Potential prophylactic role of aminoguanidine in diabetic retinopathy and nephropathy in experimental animals.
Topics: Administration, Oral; Animals; Antioxidants; Blood Glucose; Catalase; Diabetes Mellitus, Experimenta | 2009 |
Effects of aminoguanidine and vitamin C on collagen type IV in diabetic nephropathy rats.
Topics: Animals; Ascorbic Acid; Collagen Type IV; Diabetes Mellitus, Experimental; Diabetic Nephropathies; D | 2011 |
Argirein alleviates diabetic nephropathy through attenuating NADPH oxidase, Cx43, and PERK in renal tissue.
Topics: Animals; Anthraquinones; Aspartic Acid Endopeptidases; Blood Glucose; Blood Urea Nitrogen; Connexin | 2011 |
Hypoxia in the diabetic kidney is independent of advanced glycation end-products.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme Inh | 2013 |
Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephropathy in mice.
Topics: Animals; Azo Compounds; Benzoates; Blood Glucose; Body Weight; Diabetic Nephropathies; Glycation End | 2002 |
Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Diabetic Nephrop | 2002 |
ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat.
Topics: Amides; Animals; Animals, Genetically Modified; Blood Pressure; Body Weight; Diabetes Mellitus, Expe | 2002 |
Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine.
Topics: Animals; Cells, Cultured; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic | 2002 |
Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Dia | 2004 |
Davis BJ, Forbes JM, Thomas MC et al. (2004) Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 47:89-97.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Diabetic Nephrop | 2004 |
Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Extracellular Matri | 2004 |
Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation.
Topics: 2,4-Dinitrophenol; Animals; Blood Glucose; Blotting, Western; Diabetes Mellitus, Experimental; Diabe | 2005 |
From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy.
Topics: Animals; Antioxidants; Biomarkers; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetic Neph | 2005 |
Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation.
Topics: Age Factors; Binding Sites; Blotting, Western; Cells, Cultured; Diabetic Nephropathies; Dose-Respons | 2005 |
Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.
Topics: Animals; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Diabetic Nephropathies; Disease | 2007 |
Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy?
Topics: Adult; Animals; Antibodies; Cells, Cultured; Culture Media, Conditioned; Diabetes Mellitus, Experime | 2007 |
Protective effect of Liuwei Dihuang decoction on early diabetic nephropathy induced by streptozotocin via modulating ET-ROS axis and matrix metalloproteinase activity in rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dose-Response Relationship, Drug; | 2007 |
Role of maltol in advanced glycation end products and free radicals: in-vitro and in-vivo studies.
Topics: Animals; Blood Glucose; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Electro | 2008 |
Potential of aminoguanidine in diabetic CAPD patients.
Topics: Animals; Diabetic Nephropathies; Guanidines; Humans; Peritoneal Dialysis, Continuous Ambulatory; Rab | 1995 |
Administration of AGEs in vivo induces genes implicated in diabetic glomerulosclerosis.
Topics: Animals; Cell Count; Collagen; Diabetic Nephropathies; Female; Fluorescent Antibody Technique; Gene | 1995 |
Diabetic nephropathy.
Topics: Adrenergic beta-Antagonists; Aldehyde Reductase; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1994 |
The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat.
Topics: Albuminuria; Aldehyde Reductase; Animals; Antioxidants; Blood Glucose; Body Weight; Butylated Hydrox | 1995 |
High glucose concentration causes a decrease in mesangium degradation. A factor in the pathogenesis of diabetic nephropathy.
Topics: Cell Division; Cells, Cultured; Culture Media; Diabetic Nephropathies; Embryo, Mammalian; Extracellu | 1994 |
Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in streptozocin-induced diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fructo | 1996 |
Effects of heparin and aminoguanidine on glomerular basement membrane thickening in diabetic rats.
Topics: Administration, Oral; Animals; Basement Membrane; Diabetes Mellitus, Experimental; Diabetic Nephropa | 1996 |
Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glycation End Products, Advanced; | 1996 |
A curious stopping rule from Hoechst Marion Roussel.
Topics: Clinical Trials as Topic; Diabetic Nephropathies; Drug Industry; Enzyme Inhibitors; Europe; Guanidin | 1997 |
Aminoguanidine prolongs survival in azotemic-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme Inhibitors; Glycation End P | 1997 |
Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding.
Topics: Animals; Autoradiography; Binding Sites; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gl | 1999 |
Functional and structural abnormalities in the nerves of type I diabetic baboons: aminoguanidine treatment does not improve nerve function.
Topics: Aging; Animals; Axons; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Di | 2000 |
Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy.
Topics: Animals; Diabetic Nephropathies; Glycation End Products, Advanced; Guanidines; Insulin-Like Growth F | 2000 |
Renoprotective effects of a novel inhibitor of advanced glycation.
Topics: Animals; Cross-Linking Reagents; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme Inh | 2001 |
Ramipril and aminoguanidine restore renal lysosomal processing in streptozotocin diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body Weight; Chrom | 2001 |
Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy.
Topics: Animals; Autoradiography; Collagen; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene Ex | 2001 |
Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.
Topics: Animals; Collagen; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Fem | 2002 |
Effects of aminoguanidine and tolrestat on the development of ocular and renal structural changes in experimental diabetic rats.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Cataract; Diabetes Mellitus, Experimental; | 2002 |
A study on the relationship between homocysteine and diabetic nephropathy in rats.
Topics: Animals; Creatinine; Diabetic Nephropathies; Enzyme Inhibitors; Glycation End Products, Advanced; Gl | 2002 |
Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Base Sequence; Diabetes Mellitus, Experimental; D | 2002 |
Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats.
Topics: Albuminuria; Analysis of Variance; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; | 1992 |
Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat.
Topics: Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fluorescence; Glomeru | 1991 |
Monoaminoguanidine prevents sorbitol accumulation, nonenzymatic protein glycosylation and development of kidney lesions in diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glycos | 1991 |
Advanced glycosylation end-products in experimental murine diabetic nephropathy: effect of islet isografting and of aminoguanidine.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Female; Glycosylation; Guanidines; | 1989 |